Validation of a longitudinally measured surrogate marker for a time-to-event endpoint
The objective of this paper is to extend the surrogate endpoint validation methodology proposed by Buyse et al. (2000) to the case of a longitudinally measured surrogate marker when the endpoint of interest is time to some key clinical event. A joint model for longitudinal and event time data is req...
Gespeichert in:
| Veröffentlicht in: | Journal of applied statistics 2003-02, Vol.30 (2), p.235-247 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 247 |
|---|---|
| container_issue | 2 |
| container_start_page | 235 |
| container_title | Journal of applied statistics |
| container_volume | 30 |
| creator | Renard, Didier Geys, Helena Molenberghs, Geert Burzykowski, Tomasz Buyse, Marc Vangeneugden, Tony Bijnens, Luc |
| description | The objective of this paper is to extend the surrogate endpoint validation methodology proposed by Buyse et al. (2000) to the case of a longitudinally measured surrogate marker when the endpoint of interest is time to some key clinical event. A joint model for longitudinal and event time data is required. To this end, the model formulation of Henderson et al. (2000) is adopted. The methodology is applied to a set of two randomized clinical trials in advanced prostate cancer to evaluate the usefulness of prostate-specific antigen (PSA) level as a surrogate for survival. |
| doi_str_mv | 10.1080/0266476022000023776 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_repec</sourceid><recordid>TN_cdi_proquest_journals_213787153</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>655669071</sourcerecordid><originalsourceid>FETCH-LOGICAL-c557t-8c3e34e5d9b29c23f22d61ed8e332586ca5646775a05709d8416b37237fba7123</originalsourceid><addsrcrecordid>eNqFUMuO1DAQtBBIDAtfwCXiHrDdsZ25IKEVT63EheVq9cSdxUMSB9uzMH9PjwbtacVa6i4fqkpdJcRLJV8r2cs3UlvbOSu1lvw0OGcfiY0CK1tpQD8WmxOjZQo8Fc9K2TOrVwY24vo7TjFgjWlp0thgM6XlJtZDiAtO07GZCcshU2h453SDlZoZ80_KzZgy02ucqa2ppVtaakNLWFNc6nPxZMSp0It_eCGuP7z_dvmpvfr68fPlu6t2MMbVth-AoCMTtju9HTSMWgerKPQEoE1vBzS2s84ZlMbJbeg7ZXfgON-4Q6c0XIhXZ981p18HKtXv0yHz5cVrBa53nJFJcCYNOZWSafRrjhzi6JX0p_r8PfWx6stZlWml4U5ScdzjWir6Ww8IkteRh4XAEE9fnvWEYLzunP9RZzbbns3iwrXN-DvlKbDXcUp5zLgMsdx3hK9_KmvfPqiF_yX5Cxg7oO4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>213787153</pqid></control><display><type>article</type><title>Validation of a longitudinally measured surrogate marker for a time-to-event endpoint</title><source>RePEc</source><source>EBSCOhost Business Source Complete</source><creator>Renard, Didier ; Geys, Helena ; Molenberghs, Geert ; Burzykowski, Tomasz ; Buyse, Marc ; Vangeneugden, Tony ; Bijnens, Luc</creator><creatorcontrib>Renard, Didier ; Geys, Helena ; Molenberghs, Geert ; Burzykowski, Tomasz ; Buyse, Marc ; Vangeneugden, Tony ; Bijnens, Luc</creatorcontrib><description>The objective of this paper is to extend the surrogate endpoint validation methodology proposed by Buyse et al. (2000) to the case of a longitudinally measured surrogate marker when the endpoint of interest is time to some key clinical event. A joint model for longitudinal and event time data is required. To this end, the model formulation of Henderson et al. (2000) is adopted. The methodology is applied to a set of two randomized clinical trials in advanced prostate cancer to evaluate the usefulness of prostate-specific antigen (PSA) level as a surrogate for survival.</description><identifier>ISSN: 0266-4763</identifier><identifier>EISSN: 1360-0532</identifier><identifier>DOI: 10.1080/0266476022000023776</identifier><language>eng</language><publisher>Abingdon: Taylor & Francis Group</publisher><subject>Prostate cancer ; Statistical analysis ; Validation studies</subject><ispartof>Journal of applied statistics, 2003-02, Vol.30 (2), p.235-247</ispartof><rights>Copyright Taylor & Francis Group, LLC 2003</rights><rights>Copyright Carfax Publishing Company 2003</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c557t-8c3e34e5d9b29c23f22d61ed8e332586ca5646775a05709d8416b37237fba7123</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3994,27901,27902</link.rule.ids><backlink>$$Uhttp://econpapers.repec.org/article/tafjapsta/v_3a30_3ay_3a2003_3ai_3a2_3ap_3a235-247.htm$$DView record in RePEc$$Hfree_for_read</backlink></links><search><creatorcontrib>Renard, Didier</creatorcontrib><creatorcontrib>Geys, Helena</creatorcontrib><creatorcontrib>Molenberghs, Geert</creatorcontrib><creatorcontrib>Burzykowski, Tomasz</creatorcontrib><creatorcontrib>Buyse, Marc</creatorcontrib><creatorcontrib>Vangeneugden, Tony</creatorcontrib><creatorcontrib>Bijnens, Luc</creatorcontrib><title>Validation of a longitudinally measured surrogate marker for a time-to-event endpoint</title><title>Journal of applied statistics</title><description>The objective of this paper is to extend the surrogate endpoint validation methodology proposed by Buyse et al. (2000) to the case of a longitudinally measured surrogate marker when the endpoint of interest is time to some key clinical event. A joint model for longitudinal and event time data is required. To this end, the model formulation of Henderson et al. (2000) is adopted. The methodology is applied to a set of two randomized clinical trials in advanced prostate cancer to evaluate the usefulness of prostate-specific antigen (PSA) level as a surrogate for survival.</description><subject>Prostate cancer</subject><subject>Statistical analysis</subject><subject>Validation studies</subject><issn>0266-4763</issn><issn>1360-0532</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>X2L</sourceid><recordid>eNqFUMuO1DAQtBBIDAtfwCXiHrDdsZ25IKEVT63EheVq9cSdxUMSB9uzMH9PjwbtacVa6i4fqkpdJcRLJV8r2cs3UlvbOSu1lvw0OGcfiY0CK1tpQD8WmxOjZQo8Fc9K2TOrVwY24vo7TjFgjWlp0thgM6XlJtZDiAtO07GZCcshU2h453SDlZoZ80_KzZgy02ucqa2ppVtaakNLWFNc6nPxZMSp0It_eCGuP7z_dvmpvfr68fPlu6t2MMbVth-AoCMTtju9HTSMWgerKPQEoE1vBzS2s84ZlMbJbeg7ZXfgON-4Q6c0XIhXZ981p18HKtXv0yHz5cVrBa53nJFJcCYNOZWSafRrjhzi6JX0p_r8PfWx6stZlWml4U5ScdzjWir6Ww8IkteRh4XAEE9fnvWEYLzunP9RZzbbns3iwrXN-DvlKbDXcUp5zLgMsdx3hK9_KmvfPqiF_yX5Cxg7oO4</recordid><startdate>20030201</startdate><enddate>20030201</enddate><creator>Renard, Didier</creator><creator>Geys, Helena</creator><creator>Molenberghs, Geert</creator><creator>Burzykowski, Tomasz</creator><creator>Buyse, Marc</creator><creator>Vangeneugden, Tony</creator><creator>Bijnens, Luc</creator><general>Taylor & Francis Group</general><general>Taylor and Francis Journals</general><general>Taylor & Francis Ltd</general><scope>DKI</scope><scope>X2L</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7SC</scope><scope>8FD</scope><scope>H8D</scope><scope>JQ2</scope><scope>L7M</scope><scope>L~C</scope><scope>L~D</scope></search><sort><creationdate>20030201</creationdate><title>Validation of a longitudinally measured surrogate marker for a time-to-event endpoint</title><author>Renard, Didier ; Geys, Helena ; Molenberghs, Geert ; Burzykowski, Tomasz ; Buyse, Marc ; Vangeneugden, Tony ; Bijnens, Luc</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c557t-8c3e34e5d9b29c23f22d61ed8e332586ca5646775a05709d8416b37237fba7123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Prostate cancer</topic><topic>Statistical analysis</topic><topic>Validation studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Renard, Didier</creatorcontrib><creatorcontrib>Geys, Helena</creatorcontrib><creatorcontrib>Molenberghs, Geert</creatorcontrib><creatorcontrib>Burzykowski, Tomasz</creatorcontrib><creatorcontrib>Buyse, Marc</creatorcontrib><creatorcontrib>Vangeneugden, Tony</creatorcontrib><creatorcontrib>Bijnens, Luc</creatorcontrib><collection>RePEc IDEAS</collection><collection>RePEc</collection><collection>CrossRef</collection><collection>Computer and Information Systems Abstracts</collection><collection>Technology Research Database</collection><collection>Aerospace Database</collection><collection>ProQuest Computer Science Collection</collection><collection>Advanced Technologies Database with Aerospace</collection><collection>Computer and Information Systems Abstracts Academic</collection><collection>Computer and Information Systems Abstracts Professional</collection><jtitle>Journal of applied statistics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Renard, Didier</au><au>Geys, Helena</au><au>Molenberghs, Geert</au><au>Burzykowski, Tomasz</au><au>Buyse, Marc</au><au>Vangeneugden, Tony</au><au>Bijnens, Luc</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Validation of a longitudinally measured surrogate marker for a time-to-event endpoint</atitle><jtitle>Journal of applied statistics</jtitle><date>2003-02-01</date><risdate>2003</risdate><volume>30</volume><issue>2</issue><spage>235</spage><epage>247</epage><pages>235-247</pages><issn>0266-4763</issn><eissn>1360-0532</eissn><abstract>The objective of this paper is to extend the surrogate endpoint validation methodology proposed by Buyse et al. (2000) to the case of a longitudinally measured surrogate marker when the endpoint of interest is time to some key clinical event. A joint model for longitudinal and event time data is required. To this end, the model formulation of Henderson et al. (2000) is adopted. The methodology is applied to a set of two randomized clinical trials in advanced prostate cancer to evaluate the usefulness of prostate-specific antigen (PSA) level as a surrogate for survival.</abstract><cop>Abingdon</cop><pub>Taylor & Francis Group</pub><doi>10.1080/0266476022000023776</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0266-4763 |
| ispartof | Journal of applied statistics, 2003-02, Vol.30 (2), p.235-247 |
| issn | 0266-4763 1360-0532 |
| language | eng |
| recordid | cdi_proquest_journals_213787153 |
| source | RePEc; EBSCOhost Business Source Complete |
| subjects | Prostate cancer Statistical analysis Validation studies |
| title | Validation of a longitudinally measured surrogate marker for a time-to-event endpoint |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T17%3A08%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_repec&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Validation%20of%20a%20longitudinally%20measured%20surrogate%20marker%20for%20a%20time-to-event%20endpoint&rft.jtitle=Journal%20of%20applied%20statistics&rft.au=Renard,%20Didier&rft.date=2003-02-01&rft.volume=30&rft.issue=2&rft.spage=235&rft.epage=247&rft.pages=235-247&rft.issn=0266-4763&rft.eissn=1360-0532&rft_id=info:doi/10.1080/0266476022000023776&rft_dat=%3Cproquest_repec%3E655669071%3C/proquest_repec%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=213787153&rft_id=info:pmid/&rfr_iscdi=true |